LGI1-antibody associated epilepsy successfully treated in the outpatient setting
dc.catalogador | jlo | |
dc.contributor.author | Uribe-San-Martín, R. | |
dc.contributor.author | Ciampi, E. | |
dc.contributor.author | Santibañez, R. | |
dc.contributor.author | Irani, S. R. | |
dc.contributor.author | Márquez, A. | |
dc.contributor.author | Cruz, J. P. | |
dc.contributor.author | Soler, B. | |
dc.contributor.author | Miranda, M. C. | |
dc.contributor.author | Henríquez, M. | |
dc.contributor.author | Cárcamo, C. | |
dc.date.accessioned | 2024-01-19T15:29:25Z | |
dc.date.available | 2024-01-19T15:29:25Z | |
dc.date.issued | 2020 | |
dc.description.abstract | We report six patients with anti-LGI1 associated epilepsy. Two patients presented with new-onset generalized tonic-clonic seizures, four developed faciobrachial dystonic seizures and two piloerection. All patients had significant cognitive complaints at the time of diagnosis. All patients described seizure reduction during the first week of carbamazepine, and seizure freedom was obtained at a median of 13 days (range 7–22), sustained after the initiation of immunosuppression. Median time from symptom onset to carbamazepine initiation was 164 days (range 38–206 days). We discuss the particular seizure response to sodium channel blocking antiepileptic drugs, alone or associated with immunosuppression in this antibody mediated seizures. | |
dc.fechaingreso.objetodigital | 2025-01-07 | |
dc.fuente.origen | ORCID-ene24 | |
dc.identifier.doi | 10.1016/j.jneuroim.2020.577268 | |
dc.identifier.issn | 0165-5728 | |
dc.identifier.uri | http://dx.doi.org/10.1016/j.jneuroim.2020.577268 | |
dc.identifier.uri | https://repositorio.uc.cl/handle/11534/80756 | |
dc.information.autoruc | Escuela de Medicina; Uribe San Martín, Reinaldo Moisés; 0000-0002-3422-7962; 127201 | |
dc.information.autoruc | Escuela de Medicina; Ciampi Diaz, Ethel Leslie; 0000-0002-7330-5433; 132794 | |
dc.information.autoruc | Escuela de Medicina; Santibáñez Ávila, Rodrigo Andrés; 0000-0002-2391-4468; 149895 | |
dc.information.autoruc | Escuela de Medicina; Cruz Quiroga, Juan Pablo; 0000-0002-7524-7273; 17836 | |
dc.information.autoruc | Escuela de Medicina; Soler León, Bernardita María; 0000-0002-8143-4497; 189547 | |
dc.information.autoruc | Escuela de Medicina; Henríquez Baeza, Marco Antonio; S/I; 1015584 | |
dc.information.autoruc | Escuela de Medicina; Carcamo Rodriguez Claudia Andrea; 0000-0002-9430-216X; 562 | |
dc.language.iso | en | |
dc.nota.acceso | contenido completo | |
dc.pagina.final | 6 | |
dc.pagina.inicio | 1 | |
dc.revista | Journal of Neuroimmunology | |
dc.rights | acceso abierto | |
dc.subject | Leucine-rich glioma-inactivated 1 (LGI1) | |
dc.subject | Autoantibodies | |
dc.subject | Antibody mediated seizures | |
dc.subject | Autoimmune epilepsy | |
dc.subject | Carbamazepine | |
dc.subject | Neuroimmunology | |
dc.subject.ddc | 610 | |
dc.subject.dewey | Medicina y salud | es_ES |
dc.title | LGI1-antibody associated epilepsy successfully treated in the outpatient setting | |
dc.type | artículo | |
dc.volumen | 345 | |
sipa.codpersvinculados | 127201 | |
sipa.codpersvinculados | 132794 | |
sipa.codpersvinculados | 149895 | |
sipa.codpersvinculados | 17836 | |
sipa.codpersvinculados | 189547 | |
sipa.codpersvinculados | 1015584 | |
sipa.codpersvinculados | 562 | |
sipa.trazabilidad | ORCID;2024-01-08 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- LGI1-antibody associated epilepsy successfully treated in the outpatient setting.pdf
- Size:
- 942.33 KB
- Format:
- Adobe Portable Document Format
- Description: